Amycretin Novo Nordisk: Zenagamtide Results, Side Effects & 2026 Status

Amycretin Novo Nordisk searches now point to zenagamtide, and it is not FDA approved. There is no approved prescription product, price, insurance coverage, or launch date. The weekly injection reached 24.3% estimated average weight loss over 36 weeks in a small early study. The main Phase 3 obesity trial started in February 2026 and has a June 2029 primary completion date. The daily tablet now has a public Phase 3 record, but it was not yet recruiting when we checked on August 12, 2026.

That last sentence is the one nobody tells you, and it changes what you should do next. We'll get to it.

Best for you if / not for you if

This page is for you if you saw a headline about amycretin and want the real numbers, the side-effect data, where the trials actually stand, and whether there's any legitimate way to get it in 2026.

This page is not for you if you're looking for a place to buy “research amycretin” or a dosing chart. There isn't an approved product to dose, and we won't help you guess. If you want a medication you can actually discuss with a licensed clinician now, skip to what you can get today.

Amycretin at a glance

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized shortlist before you choose.

See which approved GLP-1 paths fit your situation → Free. About two minutes. No signup. You answer a few questions about your state, insurance, medication preference, and budget. You get a shortlist with verified pricing and the questions to ask before you pay.

What is amycretin from Novo Nordisk, and why is it now called zenagamtide?

Amycretin is an experimental Novo Nordisk drug for obesity and type 2 diabetes. It is one engineered peptide that activates GLP-1 and amylin receptors in the same molecule. In 2026 Novo began calling it zenagamtide, the name it now uses in press releases, trial records, and investor materials. Same candidate, new name.

Think of it like this. Semaglutide is the ingredient. Wegovy is the brand name on the box. Zenagamtide has an ingredient name, but it has no approved brand, box, or label because it is still being tested.

Novo's own materials now say “zenagamtide, formerly known as amycretin.” Its August 2026 investor presentation uses zenagamtide throughout. Amycretin still shows up in older studies, news coverage, and the search box, which is why both names live on this page.

The name and code map

This table is the most practical thing here, and it's why we built the page. If you search a trial database only for “amycretin,” you can miss records filed under the compound code.

Two things follow from that table. First, if someone hands you a “complete list of amycretin trials,” ask whether they searched NNC0487-0111 and zenagamtide too. Second, the oral and injected versions carry different project codes, which is your first clue that Novo runs them as separate programs on separate clocks. Hold that thought.

Is it a dual agonist or a triple agonist?

You'll see both labels. Novo's human clinical materials call zenagamtide a unimolecular GLP-1 and amylin receptor agonist. Some Novo scientific work also reports activity at the calcitonin receptor. That does not make it three separate drugs. The clearest plain-English description is one molecule built around GLP-1 and amylin biology.

No human study can tell you how much of the result came from each receptor. The trials test the whole molecule.

How is amycretin different from CagriSema?

People mix these up constantly, and the difference is simple.

• CagriSema = two separate drugs, semaglutide and cagrilintide, given together.
• Amycretin/zenagamtide = one molecule engineered to activate both pathways.

Same broad idea: GLP-1 plus amylin. Completely different build. CagriSema is years ahead. Novo has submitted it to the FDA and says a U.S. decision is expected in the fourth quarter of 2026. Zenagamtide has not been filed for approval.

If you want the whole family of amylin drugs compared side by side, that's our amylin agonists guide. For the live filing timeline, see our CagriSema FDA approval status guide. This page stays on zenagamtide.

Is amycretin FDA approved or available now?

No. Amycretin, now called zenagamtide, is not FDA approved. There is no approved prescription, pharmacy product, list price, savings card, insurance coverage, or announced launch date. A registered clinical trial is the normal access route. Novo also has a case-by-case expanded-access policy for serious or immediately life-threatening conditions when no satisfactory alternative exists. That is not a retail route or a routine obesity-treatment path.

Here's the part we'd rather not open with.

You can't get this drug as an approved medicine. And the number that probably brought you here — 24.3% — is the weakest number on this entire page. It came from a 125-person Phase 1b/2a study whose primary endpoint was counting treatment-emergent adverse events. Weight change was secondary. That's not a knock on the drug. It's a fact about the evidence.

Now the other side of it, because this cuts both ways.

That same fact means the real test is happening right now in Phase 3. Several injection studies are recruiting, including a study that tests whether people can maintain weight loss after a study-run-in period. It also means the honest comparison isn't “amycretin versus Wegovy.” It's “a drug with years of testing and review still ahead versus approved drugs a licensed clinician can prescribe now.” One of those paths exists today, including approved daily tablets with completed Phase 3 data.

If you came here hoping for a purchase link, this page is going to disappoint you. It may also stop you from paying a gray-market seller for a vial that is not an approved medicine. See what is actually being sold under this name.

Can a doctor prescribe amycretin?

No, not through a normal prescription. There is no FDA-approved product to write a prescription for. A doctor can help you judge whether a trial is worth discussing and help you bring the right questions to a study site.

What about expanded access?

Novo has a general expanded-access policy for some investigational medicines. A treating doctor may ask on a patient's behalf when the condition is serious or immediately life-threatening, no comparable treatment exists, and joining a trial is not possible. Novo decides case by case. We found no public zenagamtide expanded-access program, and this is not a way to buy the drug for routine weight loss.

Why “Phase 3” does not mean “almost at the pharmacy”

This trips up almost everyone. Phase 3 is the last main stage of testing. It is not the last stage of the process. Here's what still has to happen:

1. Enroll the studies and complete the planned treatment periods.
2. Clean and analyze the data.
3. Decide whether the results support an FDA application.
4. Submit a complete application.
5. Go through FDA review, questions, inspections, and label talks.
6. Receive an FDA decision.
7. Manufacture and launch the approved product.
8. Work through insurance and formulary decisions after launch.

Each step can slow down or stop. A Phase 3 start is not an approval promise. We walk through the dates in when will amycretin be available.

How much weight did people lose on amycretin?

In the early injection study, estimated average weight loss ranged from 9.7% to 24.3%, depending on dose and study length. In the early oral study, the top-dose group lost 13.1% over 12 weeks. Every one of those results came from early-stage research, not a completed Phase 3 trial.

Below is the table we built to stop the most common mistake in amycretin coverage: putting one percentage next to another when the studies were not remotely the same. Each row shows what the headline leaves out.

The amycretin headline decoder

Negative numbers mean weight lost. Positive numbers mean weight gained.

Sources: Novo Nordisk's Q2 2026 investor presentation, the peer-reviewed subcutaneous study, the peer-reviewed oral study, and Novo's ADA 2026 Phase 2 poster.

Our method note: we did not rank these rows against each other, and neither should anyone else. The studies differ in population, phase, dose, form, length, purpose, and statistical method. A bigger number in one row does not prove that dose or form would win a fair fight.

Why the 24.3% number is so easy to misuse

Five qualifiers get dropped every time it is quoted:

1. Early phase. Phase 1b/2a, not Phase 3.
2. Small. 125 people total: 101 received zenagamtide and 24 received placebo.
3. Safety first. The primary endpoint was the number of treatment-emergent adverse events. Weight was secondary.
4. Dose-escalation arm. The 60 mg figure came from a randomized escalation arm, not a long fixed-dose maintenance arm.
5. No comparison drug. There was no Wegovy arm, Zepbound arm, or other active medicine. Only placebo.

Any page telling you amycretin “beat semaglutide by 12 points” in that trial is describing a comparison that never happened.

What does “estimated mean” actually mean?

It does not mean someone guessed. Researchers use a planned statistical model to estimate the average result under the trial's stated rules, including how missing data are handled. That estimate is not the same thing as a simple raw average of every person who started. When you compare two drug headlines, check the study's analysis method as well as the percentage.

Did the weight loss plateau?

Novo reported no apparent plateau by the end of the early studies. That's genuinely encouraging. It is not proof that weight loss would keep moving at the same rate for another year. The studies ended before we could find out.

What did zenagamtide do in people with type 2 diabetes?

Across a 36-week Phase 2 program of 448 people with type 2 diabetes, the weekly injection produced up to 14.5% estimated average weight loss with an A1C drop of 1.8 percentage points, and the daily tablet produced up to 10.1% weight loss with a 1.5-point A1C drop. Up to 89.1% of people on the injection reached an A1C below 7%.

Quick translation: A1C is a blood test that reflects average blood sugar over about three months. Below 7% is a common target for many adults with type 2 diabetes, but a clinician may set a different personal target.

Doses tested ranged from 0.4 mg to 40 mg for the injection and 6 mg to 50 mg for the tablet.

Why some sources say 14.5% and others say 14.6%

Because Novo's own two documents use different rounded summaries. Its investor presentation reports 14.5% weight loss and a 1.8-point A1C drop. Its detailed June 2026 poster reports up to 14.6% weight loss and up to a 1.7-point A1C drop, plus a modeled 12.5-point weight difference versus placebo.

Neither figure changes the decision. The investor deck is a rounded summary. The poster shows the detailed analysis. We're pointing it out because a page that quietly picks the bigger number and moves on is a page that isn't reading its sources. Ours are listed at the bottom.

Why the diabetes numbers are lower than the early obesity numbers

Four differences matter, and none proves that the molecule “got weaker”:

• Different people, including people living with type 2 diabetes.
• Different main goal: A1C was the primary endpoint, not weight.
• Different doses and escalation schedules.
• Different statistical handling.

You cannot average the obesity number and the diabetes number together. They measure different things in different people.

What are amycretin's side effects — and the number nobody quotes?

The main reported side effects were nausea, vomiting, and diarrhea, and the high-dose groups had the hardest time staying on treatment. In the 262-person injected diabetes study, 16.8% of all participants discontinued trial treatment because of adverse events, mainly nausea and vomiting. In the separate dose-group table, 34% of both the 20 mg and 40 mg groups had trial treatment withdrawn after an adverse event.

Those are different denominators. The 16.8% figure covers all 262 people in the injected study. The 34% figures cover each high-dose group of 38 people.

This is the section most amycretin pages don't have, and it's the one we'd want a friend to read.

Side effects at the two highest injected doses

From Novo's detailed adverse-event table presented at the American Diabetes Association's 2026 meeting:

Overall in that injected study, 16.8% of all participants discontinued trial treatment because of adverse events.

“Mostly mild to moderate” and 34% withdrawal can both be true

This confused a lot of people online, and the explanation is worth understanding because you'll run into it with every drug in this class.

Severity describes how intense one event is. A study team may grade nausea as mild, moderate, or severe using set rules.

Tolerability describes whether a person can keep taking the medicine.

Throwing up twice a week for two months might still be graded “moderate.” And you might still quit. Both statements can be accurate. But a summary that says only “mostly mild to moderate” gives you severity and hides tolerability. Tolerability is the thing that decides whether a medicine works for you in real life, because a medicine you stop taking does nothing.

That's why we print both numbers.

The design detail that probably made it harder

Two things about how that study was built matter here:

The target doses were fixed by the trial. This was a dose-finding study, not ordinary long-term care where a clinician may hold, slow, or change a dose based on the person in front of them. That makes the high-dose dropout result important, but it does not tell us exactly what flexible dosing would do.

The top doses barely ran. People assigned to 20 mg were exposed to that maintenance dose for about eight weeks. People assigned to 40 mg had about four weeks. So the biggest efficacy numbers came with very short high-dose exposure.

Does a different Phase 3 dose ladder fix the tolerability problem? Maybe. Novo says Phase 3 is exploring doses up to 40 mg, so we're going to find out. Nobody knows yet, and anyone telling you the side effects are “manageable” is describing a hope, not a result.

What's still unknown about safety

Be honest with yourself about the size of this list:

• Long-term tolerability beyond 36 weeks at the higher doses.
• The final dose and final titration schedule.
• Rare adverse events that may appear only after thousands of people are treated.
• Safety across older adults and people with several health conditions or medicines.
• The warnings and contraindications that would appear on any future FDA label.
• What happens to weight after treatment stops.

That's a normal list for a Phase 3 drug. It's also exactly why “wait for amycretin” is a bigger bet than it sounds.

Is amycretin a pill or an injection — and which one is further along?

Both forms are in development, but they are not at the same point. Novo's August 2026 pipeline lists the injected version as “Phase 3 ongoing” and the oral version as “Phase 3 to be initiated.” The oral AMAZE 9 record was posted on ClinicalTrials.gov on July 22, 2026, but its status was still “not yet recruiting” when we checked on August 12.

This is the status split that changes the decision.

Novo said in 2025 that both forms would advance to Phase 3. The injection program is underway. The tablet now has a public record for 950 people and an estimated September 2026 start, but a planned start date is not the same thing as the first person being enrolled.

If the pill is the part you were waiting for, read this

A lot of people search amycretin for exactly one reason: they don't want to inject anything. That's a completely reasonable preference and we're not going to talk you out of it.

Here's what changed while everyone was waiting on amycretin: FDA-approved GLP-1 tablets now exist in the United States. The FDA label for Wegovy 25 mg tablets reports 13.6% estimated mean weight loss over 64 weeks, versus 2.4% with placebo, in a 307-person randomized trial. Foundayo, orforglipron, is another FDA-approved daily tablet for chronic weight management.

Compare those honestly. Amycretin's tablet: 13.1%, 12 weeks, Phase 1, 144 people across the full program, not approved, Phase 3 registered but not yet recruiting. Wegovy tablets: 13.6%, 64 weeks, completed randomized Phase 3 evidence, FDA approved.

The approved tablet has the stronger evidence and it exists. That's not a close call for someone deciding what can be prescribed now.

We come back to how to get an approved option in should you wait or start now.

Which amycretin trials are running right now?

Novo Nordisk's Phase 3 obesity program for zenagamtide is called AMAZE. Its diabetes program is called AMBITION. As of August 12, 2026, public records showed several injected AMAZE studies recruiting, two semaglutide comparison studies not yet recruiting, an oral study not yet recruiting, and a large heart-failure study recruiting.

Here's the part that took real work. Novo's investor slides show the planned program. ClinicalTrials.gov shows public records and live status. Neither source alone gives you the clean decision map. We merged them and kept “planned” separate from “recruiting.”

The AMAZE and related Phase 3 trial map

Novo's August 2026 program map also lists three planned diabetes trials:

There were also smaller Phase 1 studies recruiting on insulin regulation in type 2 diabetes and appetite and food intake in obesity: NCT07535307 and NCT07508020.

Three things this map tells you that a headline can't

1. The injection program is real and broad. It covers general obesity, type 2 diabetes, sleep apnea, knee osteoarthritis, weight maintenance, heart failure, and direct comparison with semaglutide.

2. The comparison you want has not produced an answer. AMAZE 7 and AMAZE 8 are the two public semaglutide head-to-head studies. Both were not yet recruiting at our check, so there are no results.

3. No tirzepatide head-to-head appears in the current public program. We found no trial comparing zenagamtide with tirzepatide, the ingredient in Zepbound. That means the present program cannot tell you whether zenagamtide is better than Zepbound.

How to check for a trial near you

Trial locations change. A site can be listed but not open, open but full, or recruiting only a narrow group. Use the official record for the study that fits your situation, open the Contacts and Locations section, and contact the site directly.

You can also use our GLP-1 clinical trials tracker for a plain-English map, but the ClinicalTrials.gov record is the final source for live status.

What joining a trial actually involves

Be clear-eyed about this:

• You might get placebo. Randomized studies decide by chance. You do not choose.
• Screening is real. Your weight, health history, medicines, labs, and the exact study rules matter. Many people do not qualify.
• It is a schedule. Expect visits, blood draws, questionnaires, and a study that may last well over a year.
• It ends. Ask what happens to treatment and follow-up when the study is over.

Questions worth asking the site before you commit: Is this location actively enrolling? What are the study arms? What is the visit schedule? Is travel reimbursed? What happens if I cannot tolerate the assigned dose? Who handles my care if something goes wrong? What happens after the trial ends?

A legitimate study never asks you to buy the study drug.

When will amycretin actually be available?

No approval date exists because no application has been filed. AMAZE 1 lists June 26, 2029 as its estimated primary completion date and August 21, 2029 as full study completion. Add data work, an FDA application, review, manufacturing, and launch, and 2030 to 2031 is a reasonable working range for the earliest U.S. availability — not a company date, not a promise, and only if the program succeeds.

Here's the arithmetic, laid out so you can check it yourself rather than trusting a mystery year.

What we won't do: print 2028 or 2029 as a guaranteed availability date. A trial date is not an approval date. We also will not pretend 2030 is booked. A company can file later, FDA can ask for more data, or the program can fail.

What could speed it up, and what could stop it cold

Faster: strong Phase 3 efficacy, tolerable selected doses, fast enrollment, clean manufacturing data, and a smooth FDA review.

Slower or never: enrollment trouble, high-dose tolerability problems, a safety signal, weak efficacy at the dose people can stay on, manufacturing problems, an FDA request for more data, or Novo changing priorities.

What will amycretin cost?

Novo has not announced one. There is no list price, savings program, insurance coverage for a marketed product, or Medicare position because there is no approved product. Any page giving you a monthly amycretin price is estimating, not reporting an announced price.

Should you wait for amycretin, or start something now?

For most readers who want a legitimate treatment they can start in 2026, waiting for amycretin is not a usable plan. Amycretin is still years from a possible pharmacy launch, its higher-dose tolerability is an open question, and its tablet study had not begun recruiting at our check. FDA-approved medicines with completed Phase 3 data — including daily tablets — are available now.

Find yourself in this list.

You're already on a GLP-1 and it's working. Nothing here is a reason to change it. Keep following the plan you made with your clinician. Bookmark this page and watch the dates below.

You've plateaued and want more. Do not jump to an unapproved research product. Ask your clinician whether your current dose, adherence, side effects, diagnosis, or another approved treatment path should be reviewed. AMAZE 12 is a research option for a narrow group, not a shortcut.

You wanted the pill. The amycretin tablet study was registered but not yet recruiting. FDA-approved daily tablets are already on the market with completed Phase 3 evidence. That trade is not close for someone who wants a prescription now.

You found amycretin for sale online. Please read the next section before you spend a dollar.

You're not sure which of these you are. That's the most common answer, and it's what our matching tool exists for.

The realistic move for most readers

If your goal is to make a real treatment decision before 2027 — not to be early to a molecule — the question isn't “amycretin or nothing.” It's “which approved treatment path fits my state, my health history, my insurance, and my budget?”

That's a decision with real variables: whether your plan covers a brand medicine, whether you would rather take a weekly shot or a daily tablet, and what you can afford month after month. It's the exact decision The RX Index scores treatment paths on: clinical legitimacy, care quality, transparency, access, and cost.

For readers who want an FDA-approved medicine and want help with insurance paperwork, Ro is one path worth checking. Ro's current program includes approved options such as Zepbound, Wegovy injection, Wegovy tablets, and Foundayo, subject to clinician review and current availability. Its insurance concierge applies only to the Wegovy pen, Zepbound autoinjector, and Ozempic. The tablets are cash-pay paths on Ro, not part of that insurance support.

Ro claims versus what we verified

Check what your insurance may cover on Ro → (affiliate link) The checker is free. Coverage is not guaranteed. Medication and membership are billed separately.

Ro is not for everyone. The membership does not include medication, the lowest monthly rate requires annual prepayment, and its insurance concierge does not cover every medicine Ro sells. If those tradeoffs do not fit, compare more than one route before you pay.

Our best amycretin alternatives guide compares the approved paths by pill versus injection, insurance versus cash pay, and how soon each route can actually start.

And if you have no idea which route is right, don't guess:

Get your approved GLP-1 path in about two minutes → A short list matched to your state, insurance, medication preference, and budget, with verified pricing and questions to ask before you pay.

How does amycretin compare with Wegovy, Zepbound, CagriSema, and retatrutide?

Amycretin's early numbers look strong next to approved drugs, but the comparison is not fair. The trials used different people, lengths, doses, phases, and analysis rules. The one comparison that is fair today is availability: Wegovy and Zepbound are FDA approved, while amycretin is not.

Here is the closest useful table we can build without pretending it is a leaderboard.

The table proves one thing more than any ranking: the analysis label matters. Trial-product, on-treatment, and intent-to-treat estimates answer different questions. A number can be correct inside its own study and still be wrong to compare as though every participant, rule, and week were the same.

The rule worth remembering

Compare the study design before you compare the percentages. A 36-week result from a 125-person early study is not the same kind of fact as a 64- or 72-week result from a completed Phase 3 program. If a page ranks these drugs without showing the study lengths and phases, it is entertainment, not information.

Quick answers on the specific matchups

Amycretin versus Wegovy: Amycretin's early top number is larger. Wegovy is approved, has completed Phase 3 and outcome data, and can be prescribed now. They are different categories of evidence.

Amycretin versus Zepbound: No study has produced a direct answer. No tirzepatide comparison appeared in the public zenagamtide program we checked. Anyone declaring a winner is guessing.

Amycretin versus CagriSema: Same broad biology, different build: one molecule versus two medicines given together. CagriSema is much farther along and has been submitted to FDA.

Amycretin versus retatrutide: Both are investigational, both are unavailable as approved products, and they use different receptor designs. There is no shared trial. See our retatrutide guide for that molecule.

Can you buy amycretin online? Read this before you click a listing

There is no FDA-approved amycretin or zenagamtide product to buy. We found no lawful U.S. retail or normal patient-prescription compounding path for it. A website selling a vial under this name is not selling an FDA-approved medicine, and a “research use only” label does not turn it into one.

Three questions settle this.

Is it approved? No. Novo lists it as an investigational Phase 3 candidate.

Does FDA's compounding framework support a normal zenagamtide prescription? We found zenagamtide on neither FDA's current 503A Category 1 bulk-substance list nor its 503B bulks list. It is also not the active ingredient in an FDA-approved medicine. Those facts do not support a normal U.S. patient compounding path.

Does a pharmacy stock an approved zenagamtide product? No. There is no approved product, FDA-approved label, or pharmacy list price.

What a clinical-trial dose looks like versus what's in a vial

A clinical trial uses drug made and handled under a written protocol, assigned dose groups, site oversight, labs, safety reporting, and rules for what happens when someone has a problem. A vial from a website is not that system.

A certificate of analysis tells you what a lab reported about one tested sample. It does not prove that the vial in your hand contains the same thing, has the right amount, is sterile, was stored correctly, or is safe for a human.

FDA's warning on unapproved GLP-1 products describes quality, storage, ingredient, and dosing risks. It does not make a zenagamtide vial an approved medicine. We will not name sellers, link to them, or publish dosing information, because doing that would help the exact thing we're warning you about.

One more twist coming

On May 11, 2026, MBX Biosciences said it had nominated MBX 5765 as its lead “amycretin prodrug” candidate. MBX describes it as a separate, preclinical, once-monthly multi-receptor molecule. It is not Novo Nordisk's zenagamtide.

Practical takeaway: the word “amycretin” is already being used for more than one development idea. When you see the name, check the company, compound code, trial record, and approval status before you assume it is Novo's drug.

Five things other amycretin pages get wrong

Amycretin changed names in 2026, and new trial records have appeared quickly. That has left several common claims out of date or flat wrong. Here's what we checked on August 12, 2026 and how you can verify each one yourself.

This section exists because we'd want it if we were you.

None of these pages has to be a villain. This is a fast-moving molecule that changed names mid-development. But it is why we date everything on this page and show the records behind it.

What people are actually asking about amycretin

There is no approved customer base for zenagamtide, so there are no normal product reviews or verified retail testimonials. A trial participant could discuss an experience, but an anonymous post cannot prove trial enrollment, dose, or even product identity. We did not use those posts as medical evidence.

The real questions are more useful than a fake quote:

Every one of those is answered above.

Why there are no testimonials on this page. Our brief for commercial pages asks for real customer quotes. We're not including any here, on purpose. There is no approved product and no normal customer to quote. A page that manufactured one would be lying to you about the exact thing you came here to check.

What to watch next in Novo's zenagamtide program

The next decision-grade news will come from trial status changes, results, regulatory filings, and Novo's own dated disclosures — not stock commentary or a seller's promise. Five checkpoints matter most through the end of 2026.

We sort news into three tiers so you don't have to react to everything.

Tier 1 — changes your decision: Phase 3 results · a safety signal · an FDA filing · an FDA decision · a final label · launch and pricing

Tier 2 — real progress, not a decision: First participant enrolled in oral AMAZE 9 · a new trial record · dose selection · completed enrollment · a peer-reviewed paper

Tier 3 — noise: Executive optimism · analyst price targets · stock moves · conference previews · social-media comparisons · anything a seller says

Dates and checkpoints on the calendar

We re-check this page after those events and on a quarterly schedule otherwise.

How we researched this amycretin page

We built this page from Novo Nordisk's dated documents, ClinicalTrials.gov records, FDA labels and compounding pages, the peer-reviewed papers behind the headline numbers, and official provider pages for the one commercial path discussed. Verification date: August 12, 2026.

What we verified

• Amycretin and zenagamtide are the same Novo Nordisk candidate.
• Novo's August 2026 pipeline lists injected zenagamtide as “Phase 3 ongoing” and oral zenagamtide as “Phase 3 to be initiated.”
• AMAZE 9 now has a public oral Phase 3 record, NCT07720271, but was not yet recruiting at our check.
• The dose-by-dose early injected results, the 125-person study size, and the safety-first primary endpoint.
• The oral 13.1% result at 12 weeks in the Phase 1 program.
• The diabetes results, including the 14.5% versus 14.6% rounding difference between Novo's own documents.
• The 16.8% overall adverse-event discontinuation figure, the 34% high-dose treatment-withdrawal rows, dysesthesia at 40 mg, and the four- to eight-week high-dose maintenance exposure.
• Public status, planned enrollment, and design for the Phase 3 records in the trial map.
• The FDA-label results for Wegovy tablets, Wegovy 7.2 mg, and Zepbound.
• Foundayo's April 1, 2026 FDA approval.
• FDA's current 503A and 503B compounding lists and its warnings about unapproved GLP-1 products.
• Novo's general case-by-case expanded-access policy; we found no public zenagamtide expanded-access program.
• Ro's membership price, separate medication charge, insurance-concierge scope, and live oral-treatment pages.
• MBX Biosciences' May 11, 2026 SEC filing naming MBX 5765 as a separate amycretin-prodrug candidate.

What we could not verify, and therefore did not state as fact

• Any zenagamtide FDA filing date, approval date, or launch date.
• Any zenagamtide price, savings program, or insurance position.
• The first enrolled participant in oral AMAZE 9 as of August 12, 2026.
• Public records for the planned AMBITION 1, 2, and 3 studies or AMBIENCE at our check.
• A fixed count of open sites, because location status changes.
• Any claim that zenagamtide is better than Wegovy, Zepbound, CagriSema, or retatrutide.
• The final dose, final titration schedule, or final label warnings.

Why this page exists

Because finding this out shouldn't require opening an 85-page investor deck, a conference poster, a journal article, FDA labels, and a dozen trial records — and because when we did, several common claims turned out to be wrong.

Spot an outdated trial status or a source we got wrong? Send us a correction. We log substantive fixes below with the date.

No one paid for placement on this page. Zenagamtide is not an affiliate product. Commercial links point only to approved treatment paths and are labeled.

Amycretin Novo Nordisk FAQ

Are amycretin and zenagamtide the same drug?

Yes. Zenagamtide is the name Novo Nordisk now uses for the candidate previously called amycretin. Novo's materials say “zenagamtide, formerly known as amycretin.”

Is amycretin FDA approved?

No. It is investigational. There is no FDA-approved zenagamtide product for weight loss or type 2 diabetes.

Can I buy amycretin right now?

Not as an approved medicine. We found no lawful U.S. retail or normal patient-prescription compounding path. Trials are the normal access route. Novo may consider rare expanded-access requests case by case for serious or immediately life-threatening conditions. That is not a retail path.

Is amycretin a pill or an injection?

Both are in development. The weekly injection program is underway. The once-daily tablet has a public Phase 3 record, but it was not yet recruiting on August 12, 2026.

How much weight did people lose on amycretin?

Up to 24.3% over 36 weeks at the highest injected dose in an early Phase 1b/2a study, and 13.1% over 12 weeks at the top oral dose in Phase 1. Neither result is completed Phase 3 evidence.

What are amycretin's most common side effects?

Nausea, vomiting, and diarrhea were prominent in the injected diabetes study. At the two highest injected doses, 90% of participants reported at least one adverse event, compared with 58% on placebo.

Why did 34% of people in some dose groups stop treatment?

Novo's adverse-event table records trial treatment being withdrawn after an adverse event in 34% of both the 20 mg and 40 mg groups. The separate 16.8% figure covers adverse-event discontinuations across all 262 participants in the injected study. The high-dose groups were exposed to maintenance dosing for only about eight weeks at 20 mg and four weeks at 40 mg.

Is amycretin better than Wegovy or Zepbound?

That has not been established. Two semaglutide head-to-head Phase 3 studies are registered but had not begun recruiting at our check. No tirzepatide head-to-head appeared in the public zenagamtide program.

Is amycretin the same as CagriSema?

No. CagriSema gives semaglutide and cagrilintide together. Zenagamtide is one molecule designed to activate GLP-1 and amylin receptors.

What is the AMAZE program?

AMAZE is Novo Nordisk's Phase 3 program testing zenagamtide in obesity and related conditions, including type 2 diabetes, sleep apnea, knee osteoarthritis, weight maintenance, and direct comparison with semaglutide. AMBITION is the planned diabetes program.

When will amycretin be available?

No date has been announced. AMAZE 1 has a June 2029 estimated primary completion date. A working earliest U.S. range is 2030 to 2031 if the studies succeed and the later FDA steps go well.

How much will amycretin cost?

Nothing has been announced. There is no list price, savings program, or insurance coverage because there is no approved product.

Can I join an amycretin clinical trial?

Possibly. Several injected studies were recruiting when we checked. Each trial has its own rules, and only the study team can decide whether you qualify. Oral AMAZE 9 was not yet recruiting.

Is “research grade” amycretin the real thing?

A research label does not make a vial an approved medicine. It does not prove the identity, amount, sterility, storage history, or safe human dose of the product you receive.

Still not sure which approved GLP-1 path fits you? Take our free matching quiz.

It takes about two minutes. You answer a few questions about your state, insurance, pill-versus-injection preference, and budget. You get a matched shortlist with verified pricing and questions to ask before you pay. No signup.

Update log

Primary sources

• Novo Nordisk Q2 2026 investor presentation, August 4, 2026
• Dahl K et al. Subcutaneous zenagamtide Phase 1b/2a study, The Lancet, 2025
• Gasiorek A et al. Oral zenagamtide Phase 1 study, The Lancet, 2025
• Novo Nordisk ADA 2026 subcutaneous Phase 2 poster
• ClinicalTrials.gov zenagamtide study search
• FDA Wegovy prescribing information, 2026
• FDA Zepbound prescribing information
• FDA Foundayo approval announcement, April 1, 2026
• FDA 503A bulk-substance information
• FDA 503B bulks list
• FDA concerns with unapproved GLP-1 drugs
• Novo Nordisk expanded-access policy
• Ro weight-loss pricing
• Ro insurance support
• Ro oral Wegovy page
• Ro Foundayo page
• MBX Biosciences May 11, 2026 SEC filing